Danaher (NYSE:DHR) GF Value Rank

: 6 (As of Today)

View and export this data going back to 1986. Start your Free Trial

Danaher has the GF Value Rank of 6.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison

For the Diagnostics & Research subindustry, Danaher's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Danaher GF Value Rank Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Danaher's GF Value Rank falls in comparison to its industry or sector. The grey bar indicates the GF Value Rank's extreme value range as defined by GuruFocus.

Danaher GF Value Rank Related Terms

Thank you for viewing the detailed overview of Danaher's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Danaher (NYSE:DHR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

DHR:Mexico DAPd:UK DAP:Germany DAP:Germany DAP:Germany DHER34:Brazil DHRC:Austria

Address

2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, USA, 20037-1701

Website

https://www.danaher.com

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2022, the company announced plans to divest its environmental and applied solutions group in 2023, which would leave it focused entirely on life sciences and diagnostics.

Executives

Feroz Dewan	director	C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003
Georgeann Couchara	officer: SVP, Human Resources	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Christopher Bouda	officer: VP, Chief Accounting Officer	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
A Shane Sanders	director	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Jennifer Honeycutt	officer: Executive Vice President	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jose-carlos Gutierrez-ramos	officer: SVP, Chief Scientific Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Pardis C Sabeti	director	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jessica L Mega	director	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Matthew Mcgrew	officer: EVP & Chief Financial Officer	2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010
Joakim Weidemanis	officer: Executive Vice President	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Steven M Rales	director, officer: Chairman	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Raymond C Stevens	director	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Rainer Blair	officer: Executive Vice President	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Brian W Ellis	officer: Senior Vice President - GC	2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037